- Septicemia, including serious central nervous system infections (use in combination)
- Lower respiratory tract infections (use in combination)
- Complicated urinary tract infections
- Intra-abdominal infections, including peritonitis (use in combination)
- Skin, bone, and skin structure infections (use in combination)
- Management of cystic fibrosis with P. aeruginosa (as tobramycin inhalation)
- Safety and efficacy have not been demonstrated in patients under the age of six years, patients with a forced expiratory volume in less than one second (FEV1) less than 40% or greater than 80% predicted, or patients colonized with Burkholderia cepacia.
- Treatment of ocular infections (uncomplicated conjunctivitis-ophthalmic solution)
NON-FDA APPROVED USES
- Pneumonia, hospital-acquired (in combination with a beta-lactam, beta-lactam/beta-lactamase inhibitor, or a third-/fourth-generation cephalosporin)
- Considered in patients with MDR gram negative infections.
- Efficacy is unproven.
- Pseudomonal infections (in combination with a beta-lactam, beta-lactam/beta-lactamase inhibitor, carbapenem or a third/fourth-generation cephalosporin)
- Bronchiectasis, non-cystic fibrosis (inhaled)
- Otitis external (tobramycin/dexamethasone topical)
There's more to see -- the rest of this topic is available only to subscribers.